Advanced solid tumors
NBM-BMX: Advanced Solid Tumors (Phase 1, Dose Escalation) — Completed
| Program | Preclinical | Phase I | Phase Ib/Expansion | Phase II | Phase III |
|---|---|---|---|---|---|
| Advanced solid tumors | |||||
NBM-BMX: Advanced Solid Tumors (Phase 1, Dose Escalation) — Completed
Key Results:
- 54 patients enrolled (2018–2022), including 21 Asian patients
- Well tolerated up to 400 mg/day; RP2D established at 400 mg/day (200 mg BID, fasted)
- Well tolerated up to 900 mg/day
- Stable disease (SD) observed in several patients
- No DLT reached; safety profile supports further evaluation
- Results support advancement into Phase 2 studies
Participating Sites:
- Texas Oncology
- Taipei Veterans General Hospital
- National Cheng Kung University Hospital
NBM-BMX is a novel chemical entity designed to selectively inhibit histone deacetylase 8 (HDAC8). While non-selective HDAC inhibitors face limitations in clinical applications due to significant side effects, the development of isoform-selective inhibitors like NBM-BMX offers a promising alternative. NBM-BMX has demonstrated potent anti-proliferative effects across various cancer cell types, particularly in tumors with elevated HDAC8 expression.
NBM-BMX is a novel chemical entity designed to selectively inhibit histone deacetylase 8 (HDAC8). While non-selective HDAC inhibitors face limitations in clinical applications due to significant side effects, the development of isoform-selective inhibitors like NBM-BMX offers a promising alternative. NBM-BMX has demonstrated potent anti-proliferative effects across various cancer cell types, particularly in tumors with elevated HDAC8 expression.
Recommend
Metastatic Uveal Melanoma
NBM-BMX: Metastatic Uveal Melanoma (Phase 1b/2)
Glioblastoma
NBM-BMX: Glioblastoma (TW, Phase 1b/Expansion → Phase 2)
Investigator-Initiated Trial
Hepatocellular Carcinoma：Investigator-Initiated Trial
Mesothelioma：Investigator-Initiated Trial